Back to Search
Start Over
Ultrasensitive Assay for Hepatitis B Core-Related Antigen Predicts Hepatocellular Carcinoma Incidences During Entecavir.
- Source :
-
Hepatology communications [Hepatol Commun] 2022 Jan; Vol. 6 (1), pp. 36-49. Date of Electronic Publication: 2021 Sep 16. - Publication Year :
- 2022
-
Abstract
- Serum hepatitis B core-related antigen (HBcrAg) and surface antigen (HBsAg) are surrogate markers of intrahepatic covalently closed circular DNA. The measurement range of the current HBcrAg assay is relatively narrow. Thus, we examined the potential of HBcrAg and HBsAg measured by ultrasensitive assays for predicting hepatocellular carcinoma (HCC) development in patients with chronic hepatitis B treated with entecavir (ETV). We conducted a retrospective cohort study of 180 patients who received ETV for >1 year. All patients had hepatitis B e-antigen negativity at baseline. Serum HBcrAg and HBsAg levels at baseline and year 1 were measured in all patients by ultrasensitive assays using immunoassay for total antigen including complex by pretreatment (iTACT) technology. During the median follow-up of 11.0 years, 22 patients developed HCC (11.8/1,000 person-years). Baseline HBsAg levels were not associated with HCC development during ETV treatment. However, high HBcrAg levels at baseline and at year 1 were significantly associated with HCC development (log-rank test; P < 0.001). In 110 patients (61.1%) with ≥4.0 log U/mL at baseline (high HBcrAg cohort), HBcrAg declined to ≤2.9 log U/mL at year 1 in 25 patients (22.7%). The adjusted hazard ratio for HCC incidence was significantly lower in patients with HBcrAg ≤2.9 log U/mL at year 1 than in those in the high HBcrAg cohort. Conclusion: Measurement of HBcrAg by ultrasensitive assay has better potential for predicting HCC during antiviral treatment than the current HBcrAg assay.<br /> (© 2021 The Authors. Hepatology Communications published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.)
- Subjects :
- Biomarkers, Tumor blood
DNA, Circular blood
Female
Guanine therapeutic use
Hepatitis B, Chronic blood
Humans
Male
Middle Aged
Retrospective Studies
Antiviral Agents therapeutic use
Carcinoma, Hepatocellular diagnosis
Guanine analogs & derivatives
Hepatitis B Core Antigens blood
Hepatitis B Surface Antigens blood
Hepatitis B, Chronic drug therapy
Immunoassay
Liver Neoplasms diagnosis
Subjects
Details
- Language :
- English
- ISSN :
- 2471-254X
- Volume :
- 6
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Hepatology communications
- Publication Type :
- Academic Journal
- Accession number :
- 34532993
- Full Text :
- https://doi.org/10.1002/hep4.1819